The changes mark the second major revision to the 2022 antibody-drug conjugate-focused alliance between the US and Chinese firms, which is now focusing on ADCs against Trop2, Nectin-4 and other undisclosed targets. Meanwhile, the results from other trials with Claudin 18.2 ADCs have used varying definitions of high expression, with differing results.
Merck & Co., Inc. has tweaked for the second time the lineup of antibody-drug conjugates (ADCs) it in-licensed from Chinese partner Kelun-Biotech in 2022, removing a Claudin 18.2-targeting ADC but exercising an option to add a adding a bispecific.
Claudin 18.2 has emerged as a major area of focus of R&D at innovative Chinese firms, which now have multiple...
The CEO of South Korean biotech shares how his company was able to reach a partnership with Rani so quickly and why it is confident in its GLP-1/GLP-2 dual agonist for obesity and diabetes, despite recent disappointing clinical results for its sole rival.
Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
